UNSPSC 51421604: Halobetasol or ulobetasol

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27ClF2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P6159HM7T, chemically known as 21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate but generally known as halobetasol, which bears US NIH Compound Identifier 48175. European Medicines Agency schedules Halobetasol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11379MIG.

World Health Organization schedules halobetasol in its Anatomical Therapeutic Chemical (ATC) Classification. Halobetasol or ulobetasol bears US NLM identifiers UMLS ID C0082787 and NCI Concept Code C61781. SMILES: CLCC(=O)C1(OC(=O)CC)C2(C(C3C(F)(C(O)C2)C2(C(=CC(=O)C=C2)C(F)C3)C)CC1C)C.

UNSPSC 51421604 Halobetasol or ulobetasol is a Commodity code that shows a significant mismatch between its nominal scope and actual state and local procurement activity. The single recent opportunity tagged under this code—Seminole County, Florida's IFB60459723LAS—solicits naloxone and safe drug deactivation systems for community health support, not topical corticosteroid pharmaceuticals as the code name suggests. The procurement calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, and includes standard compliance requirements such as drug-free workplace certification, E-Verify eligibility confirmation, workers' compensation and commercial general liability insurance, and potential FEMA funding with associated federal environmental compliance obligations.

The recent activity is confined to Seminole County, Florida, with an IFB response deadline of July 26, 2023. No other state or local jurisdictions appear in the source data under this code, and the single opportunity does not reflect the code's stated pharmaceutical purpose. This code appears to see minimal relevant activity in state and local procurement, or the tagging of this particular opportunity may represent a data-classification error. Business development professionals should verify whether opportunities in topical corticosteroids or related dermatological pharmaceuticals are being issued under alternative UNSPSC codes before deciding to pursue activity in this category.